Dr. Lloyd Miller, MD, PhD, Vice President, Immunodermatology Disease Area Leader at Janssen, discusses new data presented at the 2021 European Academy of Dermatology Venereology Congress (EADV) showing TREMFYA provided durable complete and almost complete skin clearance responses and was well-tolerated with low risk of infection and low rates of anti-drug antibodies in psoriasis (PsO) through up to five years. The patient population studied included PsO patients who switched to TREMFYA from adalimumab. Lloyd talks about what these results mean for patients and healthcare providers.
Lloyd S. Miller, M.D., Ph.D., is Vice President, Immunodermatology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Lloyd drives the development and implementation of the scientific strategy for immunodermatology to help meet the needs of the millions of patients living with immune-mediated skin diseases.
Prior to Janssen, Lloyd served as Vice Chair for Research in Dermatology within the Department of Dermatology at Johns Hopkins. He was also a Professor of Dermatology, Infectious Diseases, Orthopedic Surgery and Materials Science and Engineering at the Johns Hopkins University School of Medicine.
A known leader in dermatology, Lloyd has published more than 100 peer-reviewed manuscripts, review articles, book chapters and editorials and has given more than 75 oral presentations at national and international scientific programs and meetings. Lloyd has received several grants from the National Institutes of Health (NIH), in addition to private foundation and industry funding for his research.
Lloyd received his M.D. and Ph.D. from the State University of New York Downstate Medical Center in Brooklyn, New York. He completed his dermatology residency and post-doctoral research fellowship in the Specialty Training and Advanced Research program at the University of California, Los Angeles.